Clinical Trials Logo

Tachycardia clinical trials

View clinical trials related to Tachycardia.

Filter by:
  • Enrolling by invitation  
  • « Prev · Page 2

NCT ID: NCT03218761 Enrolling by invitation - Clinical trials for Postural Tachycardia Syndrome

POTS NET mRNA Functional Correlation With NET Activity

Start date: July 14, 2017
Phase:
Study type: Observational [Patient Registry]

DNA Acetylation can be responsible for significant down-regulation of transcription of the Norepinephrine Transporter (NET). NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses. Very low levels of NET can "cause" Postural Tachycardia Syndrome (POTS) or make these patients more susceptible to certain medications. Quantified NET messenger RNA (mRNA) levels from a peripheral blood sample may be able to assess NET availability, which is simpler than older methods. This has not been validated against NET function. In this protocol, the investigators seek to assess whether these NET mRNA levels correlate with NET function. The investigators will assess the DHPG (NET dependent NE metabolite):NE ratio in POTS patients and control subjects from both plasma and urine samples.

NCT ID: NCT02962076 Enrolling by invitation - Clinical trials for Ventricular Tachycardia

Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia

Start date: September 21, 2020
Phase: Early Phase 1
Study type: Interventional

Imaging is to be performed prior to procedure using positron emission tomography/ computed tomography (PET/CT), after a special dye is injected. The scans are going to be merged with other cardiac scans when doing the ablation procedure to correlate anatomy with physiology.

NCT ID: NCT02725060 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

Autoimmune Basis for Postural Tachycardia Syndrome

Start date: February 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to see if some people with postural tachycardia syndrome (POTS) have higher levels of immune proteins (autoantibodies) directed against receptors of the autonomic nervous system, and if these autoantibodies make a difference in their POTS symptoms. The investigators also want to see if the levels of these autoantibodies stay the same over time.

NCT ID: NCT02413450 Enrolling by invitation - Clinical trials for Hypertrophic Cardiomyopathy (HCM)

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

Start date: August 2013
Phase:
Study type: Observational [Patient Registry]

Human induced pluripotent stem cells (hiPSCs) have driven a paradigm shift in the modeling of human disease; the ability to reprogram patient-specific cells holds the promise of an enhanced understanding of disease mechanisms and phenotypic variability, with applications in personalized predictive pharmacology/toxicology, cell therapy and regenerative medicine. This research will collect blood or skin biopsies from patients and healthy controls for the purpose of generating cell and tissue models of Mendelian heritable forms of heart disease focusing on cardiomyopathies, channelopathies and neuromuscular diseases. Cardiomyocytes derived from hiPSCs will provide a ready source of disease specific cells to study pathogenesis and therapeutics.

NCT ID: NCT02031484 Enrolling by invitation - Atrial Fibrillation Clinical Trials

Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial

Start date: July 2016
Phase: N/A
Study type: Observational

This study is intended to compare the new Carnation patch monitoring system with the Zio patch, which represents the current standard for continuous recording of the ECG over extended periods.

NCT ID: NCT01761825 Enrolling by invitation - Clinical trials for Postural Tachycardia Syndrome

The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome

Start date: December 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Ivabradine is an effective treatment for postural tachycardia syndrome.